+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2013-01-16Number of Pages: 112

Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast 2012 - 2018

Global Liver Diseases Therapeutics Market: Snapshot

The global market for liver diseases therapeutics is witnessing increasing traction globally owing to factors such as the rapid rise in the world’s population of geriatrics, rising prevalence of liver diseases, and the presence of vast unmet needs in the field of liver cancer treatment. The liver disease therapeutics market is also driven by the increased focus of developing economies on undertaking vaccination drives to reduce the occurrence of chronic diseases. The large number of highly anticipated and potentially strong and effective liver disease drugs presently undergoing clinical trials or in the pipeline is also expected to lead to promising growth opportunities for the global liver disease therapeutics market. 

Transparency Market Research states that the global liver diseases market will witness vast developments in the next few years as pharmaceutical companies continue to invest vast funds on the development of new drug varieties and newer technologies such as nanotechnology become increasingly accessible. As a result, the global liver diseases therapeutics market will exhibit a healthy 8.60% CAGR from 2012 through 2018, rising from a valuation of US$6.5 bn in 2011 to US$10.9 bn by 2018. 

Anti-viral Drug Category to Continue to Rake in Dominant Share in Global Market

On the basis of drug class, the global liver disease therapeutics market is segmented into immunosuppressants, targeted therapy drugs, chemotherapy drugs anti-viral drugs, vaccines, and corticosteroids. Of these, the segment of anti-viral drugs accounts for a massive chunk of the overall revenue of the global liver diseases therapeutics market. The market for anti-viral drugs for liver diseases was valued at US$2,817.2 mn in 2015 and is expected to rise to US$3,580.8 million in 2018. The segment will continue to be the leading contributor of revenue to the global liver diseases therapeutics market, exhibiting a promising 8.3% CAGR over the report’s forecast period.

Nevertheless, the chemotherapy drugs segment will exhibit the most promising growth rate over the forecast period and emerge as the most lucrative drug class in terms of returns on investment. The segment is expected to exhibit a massive 43% CAGR over the report’s forecast period. The segment will chiefly benefit from the approval and commercialization of several anticipated pipeline drugs. 

Emerging Economies to Provide Lucrative Growth Opportunities

High incidence of liver diseases across emerging economies in regions such as Asia Pacific, Latin America, and Eastern Europe is a leading factor bolstering the growth prospects of the liver diseases therapeutics market in these regions. It is estimated that these regions and the development of the market across them will be a key determinant of the growth of the global liver diseases therapeutics market. 

To exploit the vast growth opportunities across these regions, companies such as Novartis and GSK are establishing their operations across countries such as China and India to begin a sustainable and parallel source of revenue generation. Many other pharmaceutical companies are also establishing research laboratories and R&D facilities across these regions and the number is expected to continue to rise in the next few years. 

The global liver diseases therapeutics market features an oligopolistic competitive landscape and the top five vendors collectively account for a massive chunk of the overall market. The market exhibits very high entry barriers for new vendors owing to capital intensive drug development and research activities and strict FDA norms regarding drug approval. Some of the key vendors in the market are GlaxoSmithKline Pharmaceuticals Limited, Crucell, Pfizer, Merck & Co., Gilead Science Inc., Astellas Pharma Inc., Abbot Laboratories, Novartis, Bristol-Myers Squibb, and Roche. 

Table of Content

CHAPTER 1 PREFACE
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SIZE
3.3 COMPARATIVE ANALYSIS OF GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 & 2018
3.4 LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
      3.4.1 DRIVERS
              3.4.1.1 Aging population inducing chronic liver diseases such as hepatitis and liver cancer
              3.4.1.2 Increasing global prevalence of liver diseases
              3.4.1.3 High unmet needs exist in the liver cancer therapeutics
              3.4.1.4 Increased vaccination in emerging economies
      3.4.2 LIVER DISEASE THERAPEUTICS MARKET DRIVERS IMPACT ANALYSIS
      3.4.3 RESTRAINTS
              3.4.3.1 Side-effects and risks
              3.4.3.2 FDA approvals and other government regulations
              3.4.3.3 Availability of alternate treatment procedures
      3.4.4 LIVER DISEASE THERAPEUTICS MARKET RESTRAINTS IMPACT ANALYSIS
      3.4.5 OPPORTUNITIES
              3.4.5.1 Strong pipeline drugs
              3.4.5.2 Emerging economies in Asia, Latin America and Eastern European countries
              3.4.5.3 Consolidation opportunities in the healthcare industry
3.5 PORTER’S FIVE FORCES ANALYSIS FOR LIVER DISEASES THERAPEUTICS MARKET
      3.5.1 BARGAINING POWER OF SUPPLIERS
      3.5.2 BARGAINING POWER OF BUYERS
      3.5.3 THREAT OF NEW ENTRANTS
      3.5.4 THREAT OF SUBSTITUTES
      3.5.5 COMPETITIVE RIVALRY

CHAPTER 4 LIVER DISEASES CLASSIFICATION AND THERAPY OPTIONS
4.1 ALCOHOL INDUCED LIVER DISEASE
      4.1.1 OVERVIEW
      4.1.2 EPIDEMIOLOGY
      4.1.3 ETIOLOGY
      4.1.4 SYMPTOMS
      4.1.5 PATHOPHYSIOLOGY
      4.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
              4.1.6.1 Anabolic Steroids
              4.1.6.2 Alcohol Abuse Drugs
4.2 AUTOIMMUNE LIVER DISORDER
      4.2.1 AUTOIMMUNE HEPATITIS (AIH)
              4.2.1.1 OVERVIEW
              4.2.1.2 EPIDEMIOLOGY
              4.2.1.3 ETIOLOGY
              4.2.1.4 SYMPTOMS
              4.2.1.5 PATHOPHYSIOLOGY
              4.2.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
                        4.2.1.6.1 Antimetabolites
                        4.2.1.6.2 Corticosteroids
4.3 HEPATOCELLULAR CARCINOMA
      4.3.1 OVERVIEW
      4.3.2 EPIDEMIOLOGY
      4.3.3 ETIOLOGY
      4.3.4 SYMPTOMS
      4.3.5 PATHOPHYSIOLOGY
      4.3.6 TREATMENT PATTERN AND THERAPY OPTIONS
              4.3.6.1 Chemotherapy
              4.3.6.2 Targeted Therapy
4.4 NON-ALCOHOLIC FATTY LIVER DISEASE
      4.4.1 OVERVIEW
      4.4.2 EPIDEMIOLOGY
      4.4.3 ETIOLOGY
      4.4.4 SYMPTOMS
      4.4.5 PATHOPHYSIOLOGY
      4.4.6 TREATMENT PATTERN AND THERAPY OPTIONS
              4.4.6.1 Gallstone solubilising drugs
4.5 VIRAL/HEPATITIS LIVER DISORDER
      4.5.1 HEPATITIS A
              4.5.1.1 OVERVIEW
              4.5.1.2 EPIDEMIOLOGY
              4.5.1.3 ETIOLOGY
              4.5.1.4 SYMPTOMS
              4.5.1.5 PATHOPHYSIOLOGY
              4.5.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
                        4.5.1.6.1 Vaccines
                        4.5.1.6.2 Immunoglobulins
      4.5.2 HEPATITIS B
              4.5.2.1 OVERVIEW
              4.5.2.2 EPIDEMIOLOGY
              4.5.2.3 ETIOLOGY
              4.5.2.4 SYMPTOMS
              4.5.2.5 PATHOPHYSIOLOGY
              4.5.2.6 TREATMENT PATTERN AND THERAPY OPTIONS
                        4.5.2.6.1 Antiviral drugs
                        4.5.2.6.2 Immunoglobulins
                        4.5.2.6.3 Vaccines
      4.5.3 HEPATITIS C
              4.5.3.1 OVERVIEW
              4.5.3.2 EPIDEMIOLOGY
              4.5.3.3 ETIOLOGY
              4.5.3.4 SYMPTOMS
              4.5.3.5 PATHOPHYSIOLOGY
              4.5.3.6 TREATMENT PATTERN AND THERAPY OPTIONS
                        4.5.3.6.1 Antiviral drugs
      4.5.4 HEPATITIS D
              4.5.4.1 OVERVIEW
              4.5.4.2 EPIDEMIOLOGY
              4.5.4.3 ETIOLOGY
              4.5.4.4 SYMPTOMS
              4.5.4.5 PATHOPHYSIOLOGY
              4.5.4.6 TREATMENT PATTERN AND THERAPY OPTIONS
      4.5.5 HEPATITIS E
              4.5.5.1 OVERVIEW
              4.5.5.2 EPIDEMIOLOGY
              4.5.5.3 ETIOLOGY
              4.5.5.4 SYMPTOMS
              4.5.5.5 PATHOPHYSIOLOGY
              4.5.5.6 TREATMENT PATTERN AND THERAPY OPTIONS

CHAPTER 5 LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS
5.1 IMMUNOSUPPRESSANTS
      5.1.1 GLOBALIMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.2 CHEMOTHERAPY DRUGS
      5.2.1 GLOBAL CHEMOTHERAPY DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.3 TARGETED THERAPY DRUGS
      5.3.1 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.4 VACCINES
      5.4.1 GLOBAL VACCINES MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.5 ANTI-VIRAL DRUGS
      5.5.1 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.6 IMMUNOGLOBULINS
      5.6.1 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.7 CORTICOSTERIODS
      5.7.1 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)

CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 MARKET SHARE OF KEY PLAYERS IN LIVER DISEASES THERAPEUTICS MARKET BY DRUG CLASS
      6.1.1 MARKET SHARE OF KEY PLAYERS FORIMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES
      6.1.2 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES
      6.1.3 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES
      6.1.4 MARKET SHARE OF KEY PLAYERS FOR TARGETED THERAPY FOR LIVER DISEASES
      6.1.5 NEW ENTRANTS (PHASE III)
      6.1.6 COMPETITIVE STRATEGY BY KEY PLAYERS
              6.1.6.1 Investments in R&D and clinical studies
              6.1.6.2 Entering the emerging economies
              6.1.6.3 Investing in different segments of the market
      6.1.7 COMPETITIVE STRATEGY BY NEW ENTRANTS
      6.1.8 AGREEMENTS AND COLLABORATIONS

CHAPTER 7 RECOMMENDATIONS
7.1 MARKET STRATEGY FOR SUCCESS
7.2 BARRIERS TO BE CONSIDERED

CHAPTER 8 COMPANY PROFILES
8.1 ABBOTT LABORATORIES
      8.1.1 COMPANY OVERVIEW
      8.1.2 FINANCIAL OVERVIEW
      8.1.3 BUSINESS STRATEGIES
              8.1.3.1 Significant R&D investments for new products development
              8.1.3.2 Investing in emerging markets
              8.1.3.3 Conducting clinical trials
      8.1.4 PRODUCT PORTFOLIO
      8.1.5 RECENT DEVELOPMENTS
8.2 ASTELLAS PHARMA INC.
      8.2.1 COMPANY OVERVIEW
      8.2.2 FINANCIAL OVERVIEW
      8.2.3 BUSINESS STRATEGIES
              8.2.3.1 Investing in emerging economies
              8.2.3.2 Investing in research and development
      8.2.4 PRODUCT PORTFOLIO
      8.2.5 RECENT DEVELOPMENTS
8.3 BRISTOL-MYERS SQUIBB
      8.3.1 COMPANY OVERVIEW
      8.3.2 FINANCIAL OVERVIEW
      8.3.3 BUSINESS STRATEGIES
              8.3.3.1 Mergers, acquisitiosn and strategic development
              8.3.3.2 Investing in research and development
      8.3.4 PRODUCT PORTFOLIO
      8.3.5 RECENT DEVELOPMENTS
8.4 GILEAD SCIENCES
      8.4.1 COMPANY OVERVIEW
      8.4.2 FINANCIAL OVERVIEW
      8.4.3 BUSINESS STRATEGIES
              8.4.3.1 Innovative new products
              8.4.3.2 Investing in research and development
      8.4.4 PRODUCT PORTFOLIO
      8.4.5 RECENT DEVELOPMENTS
8.5 GLAXOSMITHKLINE PLC
      8.5.1 COMPANY OVERVIEW
      8.5.2 FINANCIAL OVERVIEW
      8.5.3 BUSINESS STRATEGIES
              8.5.3.1 Research and development investments
              8.5.3.2 Delivering new products
      8.5.4 PRODUCT PORTFOLIO
      8.5.5 RECENT DEVELOPMENTS
8.6 F. HOFFMANN-LA ROCHE LTD
      8.6.1 COMPANY OVERVIEW
      8.6.2 FINANCIAL OVERVIEW
      8.6.3 BUSINESS STRATEGIES
              8.6.3.1 Strategic alliance initiative
              8.6.3.2 Investing in research and development
      8.6.4 PRODUCT PORTFOLIO
      8.6.5 RECENT DEVELOPMENTS
8.7 MERCK & CO. INC
      8.7.1 COMPANY OVERVIEW
      8.7.2 FINANCIAL OVERVIEW
      8.7.3 BUSINESS STRATEGIES
              8.7.3.1 R&D initiatives
              8.7.3.2 Strategic alliance
              8.7.3.3 Corporate social responsibility and awareness
      8.7.4 PRODUCT PORTFOLIO
      8.7.5 RECENT DEVELOPMENTS
8.8 NOVARTIS AG
      8.8.1 COMPANY OVERVIEW
      8.8.2 FINANCIAL OVERVIEW
      8.8.3 BUSINESS STRATEGIES
              8.8.3.1 Strategic alliance
              8.8.3.2 Investing in research and development
      8.8.4 PRODUCT PORTFOLIO
      8.8.5 RECENT DEVELOPMENTS
8.9 SANOFI S.A
      8.9.1 COMPANY OVERVIEW
      8.9.2 FINANCIAL OVERVIEW
      8.9.3 BUSINESS STRATEGIES
              8.9.3.1 Business Diversification
              8.9.3.2 Research and development initiative
      8.9.4 PRODUCT PORTFOLIO
      8.9.5 RECENT DEVELOPMENTS
8.10 PFIZER INC.
      8.10.1 COMPANY OVERVIEW
      8.10.2 FINANCIAL OVERVIEW
      8.10.3 BUSINESS STRATEGIES
8.10.3.1 Investing in research and development
      8.10.4 PRODUCT PORTFOLIO
      8.10.5 RECENT DEVELOPMENTS
8.11 TAKEDA PHARMACEUTICAL
      8.11.1 COMPANY OVERVIEW
      8.11.2 FINANCIAL OVERVIEW
      8.11.3 BUSINESS STRATEGIES
8.11.3.1 Investing in emerging economies
8.11.3.2 Investing in research and development
      8.11.4 PRODUCT PORTFOLIO
      8.11.5 RECENT DEVELOPMENTS
8.12 VALEANT PHARMACEUTICALS
      8.12.1 COMPANY OVERVIEW
      8.12.2 FINANCIAL OVERVIEW
      8.12.3 BUSINESS STRATEGIES
8.12.3.1 Strategic alliance
      8.12.4 PRODUCT PORTFOLIO
      8.12.5 RECENT DEVELOPMENTS
8.13 WATSON PHARMACEUTICALS, INC.
      8.13.1 COMPANY OVERVIEW
      8.13.2 FINANCIAL OVERVIEW
      8.13.3 BUSINESS STRATEGIES
              8.13.3.1 Investing in generic and biosimilar segments
              8.13.3.2 Investing in research and development
      8.13.4 PRODUCT PORTFOLIO
      8.13.5 RECENT DEVELOPMENTS

LIST OF FIGURES

FIG. 1 GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 (USD MILLION)
FIG. 2 LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION
FIG. 3 COMPARATIVE MARKET SHARE ANALYSIS OF GLOBAL LIVER DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2011 & 2018
FIG. 4 PORTER’S FIVE FORCES ANALYSIS FOR THE LIVER DISEASES THERAPEUTICS MARKET
FIG. 5 PROGRESSION OF ALCOHOL INDUCED LIVER DISEASE IN HEAVY DRINKERS
FIG. 6 PROGRESSION OF HEPATOCELLULAR CANCER
FIG. 7 TWO-HIT CONCEPT OF NON-ALCOHOLIC FATTY LIVER DISEASE
FIG. 8 PATHOGENESIS OF HEPATITIS A VIRUS
FIG. 9 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
FIG. 10 GLOBAL CHEMOTHERAPY MARKET FOR LIVER DISEASE THERAPEUTICS , 2010 – 2018 (USD MILLION)
FIG. 11 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010– 2018 (USD MILLION)
FIG. 12 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 – 2018 (USD MILLION)
FIG. 13 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 – 2018 (USD MILLION)
FIG. 14 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 – 2018 (USD MILLION)
FIG. 15 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 16 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 17 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 18 ABBOTT LABORATORIES NET SALES, 2008-2011 (USD MILLION)
FIG. 19 ASTELLAS PHARMA INC. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 20 BRISTOL-MYERS SQUIBB ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 21 GILEAD SCIENCE ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 22 GLAXO SMITHKLINE ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 23 F. HOFFMANN-LA ROCHE LTD. ANNUAL SALES, 2007-2011 (USD MILLION)
FIG. 24 MERCK & CO, INC. ANNUAL REVENUE, 2007 – 2011 (USD MILLION)
FIG. 25 NOVARTIS AG. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 26 SANOFI SA. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 27 PFIZER INC. ANNUAL REVENUE, 2009-2011 (USD MILLION)
FIG. 28 TAKEDA INC. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 29 VALEANT PHARMACEUTICAL ANNUAL REVENUE, 2008-2011 (USD MILLION)
FIG. 30 WATSON PHARMACEUTICALS INC., 2007-2011 (USD MILLION)

 

LIST OF TABLES

TABLE 1 GLOBAL LIVER DISEASES THERAPEUTICS MARKET: SNAPSHOT
TABLE 2 GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2010 - 2018
TABLE 3 IMPACT ANALYSIS OF DRIVERS
TABLE 4 IMPACT ANALYSIS OF RESTRAINTS
TABLE 5 PIPELINE DRUGS FOR LIVER DISEASES THERAPEUTICS (PHASE III)
TABLE 6 RECENT AGREEMENT AND COLLABORATION OF KEY PLAYERS

The report on “Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 – 2018” studies the performance of the different drugs class segments that are employed in liver disease therapeutics. These performance analyses have been performed based on revenue.

The report provides the market size of the liver diseases therapeutics market before carrying out a comparative analysis of the global liver disease therapeutics market based on drug class. The first two chapters offer an orientation of the general trends in the liver diseases therapeutics market.

It further touches upon the various market drivers that have created numerous opportunities within this market—such as an aging population, a rise in the global prevalence of liver disease, the presence of high unmet needs in liver cancer therapeutics, and the increasing volume of vaccination in developing economies.

Furthermore, this data-driven report also offers insights into factors that could prove to be impediments to the ideal growth of this market. These include: side effects and risks associated with some of these drugs, government regulations as well as FDA approvals, and the availability of alternative treatments to patients.

The report classifies the global liver diseases therapeutics market based on the key prevailing drug class segments. These seven segments are: immunosuppressants, anti-viral drugs, immunoglobulins, chemotherapy, targeted therapy, vaccines, and corticosteroids. Going ahead, the report also provides detailed estimates and forecasts of the market size from 2012 – 2018, coupled with the compounded annual growth rate (CAGR) of each of these segments. 

This report has been designed to offer users an unmatched competitive edge, and hence features an in-depth competitive landscape of the liver diseases therapeutics market, with complete company profiles of market players that matter. These include names such as: Astellas Pharma Inc, Novartis, Abbott Laboratories, Gilead Science Inc., Pfizer, Merck & Co., Roche, as well as Bristol-Myers Squibb, among others

The report presents a complete analysis of the company overview, business strategies, product portfolio, recent developments, and a financial overview of these companies.

The report answers questions pertaining to the performance of liver diseases therapeutics in the worldwide market, as well as the role played by emerging markets in their performance. The report is based on in-depth and accurate primary and secondary research methodologies that have been perfected by the research team at Transparency Market Research. Our findings are further validated via analysis and consultations with C-level executives working with major companies in the liver diseases therapeutics market. 

The report classifies liver diseases and therapy options as follows:

  • Alcohol induced liver disease
  • Autoimmune liver disorder
  • Hepatocellular carcinoma
  • Non-alcoholic fatty liver disease
  • Viral/hepatitis liver disorder

The report also studies the liver diseases therapeutics market based on drug class, as follows:

  • Immunosuppressants
  • Chemotherapy drugs
  • Targeted therapy drugs
  • Vaccines
  • Anti-viral drugs
  • Immunoglobulins
  • Corticosteriods

The report offers a comprehensive overview of idea market strategies for success as well as key barriers to be considered when entering or undertaking expansion in the liver disease therapeutics market.


 
 
Back To Top